연구동향 분석

원저 : 류마티스관절염에서 DAS28에 근거한 보험급여기준 적용시 항 TNF제제 대상 환자 예측

원소영 ( Soyoung Won ) 성윤경 ( Yoon Kyoung Sung ) 조수경 ( Soo Kyung Cho ) 최찬범 ( Chan Bum Choi ) 고은미 ( Eun Mi Koh ) 김성규 ( Seong Kyu Kim ) 김진석 ( Jinseok Kim ) 김태환 ( Tae Hwan Kim ) 김현아 ( Hyoun Ah Kim ) 나성수 ( Seong Su Nah ) 방소영 ( So Young Bang ) 2014년

논문상세정보
인용/피인용
' 원저 : 류마티스관절염에서 DAS28에 근거한 보험급여기준 적용시 항 TNF제제 대상 환자 예측' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • das28
  • koreannationalhealthinsurancereimbursementcriteria
  • rheumatoid arthritis
  • tnfinhibitor
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
203 0

0.0%

' 원저 : 류마티스관절염에서 DAS28에 근거한 보험급여기준 적용시 항 TNF제제 대상 환자 예측' 의 참고문헌

  • 류마티스관절염 환자에서 미국, 영국, 일본 류마티스학회 TNF-α 길항제 사용 가이드라인과 한국의료보험 급여기준 비교 조사
    손경민 대한류마티스학회지 19 (6) : 334 ~ 340 [2012]
  • 류마티스관절염 치료에서 종양괴사인자억제제 사용에 대한 고찰
    송정수 대한류마티스학회지 14 (1) : 1 ~ 14 [2007]
  • Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?
    Putrik P Ann Rheum Dis [2013]
  • Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
    Wells G Ann Rheum Dis 68 : 954 ~ 960 - [2009]
  • Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)
    Ledingham J Rheumatology (Oxford) 44 : 157 ~ 163 - [2005]
  • The problem of rheumatoid arthritis disease activity and remission in clinical practice
    Shaver TS J Rheumatol 35 : 1015 ~ 1022 - [2008]
  • The influence of the definition of patient global assessment in assessment of disease activity according to the Disease Activity Score (DAS28) in rheumatoid arthritis
    Dougados M J Rheumatol 38 : 2326 ~ 2328 - [2011]
  • The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis
    Gartlehner G J Rheumatol 33 : 2398 ~ 2408 [2006]
  • Rheumatoid arthritis
    Lee DM Lancet 358 : 903 ~ 911 - [2001]
  • Prevalence and incidence of rheumatoid arthritis in South Korea
    Sung YK Rheumatol Int 33 : 1525 ~ 1532 - [2013]
  • National Health Insurance Administration
  • Japan College of Rheumatology. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis
    Koike R Mod Rheumatol 17 : 451 ~ 458 [2007]
  • Health Insurance Review & Assessment Service
    [2013]
  • Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis
    Abdel-Nasser AM Semin Arthritis Rheum 27 : 123 ~ 140 - [1997]
  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
    Smolen JS Ann Rheum Dis 69 : 964 ~ 975 - [2010]
  • Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan
    Matsui T Ann Rheum Dis 66 : 1221 ~ 1226 - [2007]
  • DAS score
  • Comparison of composite disease activity indices for rheumatoid arthritis
    Matsui T Mod Rheumatol 21 : 134 ~ 143 - [2011]
  • Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values
    Inoue E Ann Rheum Dis 66 : 407 ~ 409 - [2007]
  • Are the C-reactive protein values and erythrocyte sedimentation rate equivalent when estimating the 28-joint disease activity score in rheumatoid arthritis?
    Castrejón I Clin Exp Rheumatol 26 : 769 ~ 775 - [2008]
  • 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
    Singh JA Arthritis Care Res (Hoboken) 64 : 625 ~ 639 - [2012]